Pfizer stock has clawed back some ground over the past year but is still down sharply over five years, and the current valuation checks point to something closer to a middle ground than a clear bargain or an obvious premium.

• Pfizer shares have declined 23.5% over the past five years, which leaves long term holders with a weak overall return and raises the question of whether today’s price now roughly reflects that reset.
• Regulatory wins in oncology and weight loss treatments may support expectations for future cash flows, while ongoing patent disputes around COVID 19 vaccines highlight legal and intellectual property risks that can weigh on what investors are willing to pay.
• On Simply Wall St’s broader valuation checks, Pfizer earns a mixed score of 4 out of 6. This suggests the stock is neither a clear bargain nor clearly expensive on the usual metrics.

The issue now is whether Pfizer’s current share price already captures this mix of recovering sentiment and lingering risks, or if there is still a meaningful gap between expectations and what the business is worth.

Does Pfizer Look Fairly Valued on Earnings?

The P/E ratio is a useful yardstick for a mature drug maker like Pfizer because earnings are a key driver of how investors value large pharmaceutical companies. Pfizer currently trades on a P/E of 18.9x, compared with the pharmaceuticals industry average of 14.9x and a broader peer average of about 26.3x, so the stock sits between cheaper sector peers and higher rated large competitors.

Simply Wall St’s fair P/E for Pfizer is 19.7x, which reflects what investors might expect to pay given its margins, size, industry and risk profile. That is close to the current 18.9x multiple, which suggests only a small gap between where the stock trades and where this framework indicates it could sit. Despite recent headlines around new oncology approvals and weight loss drug progress, the market is still pricing Pfizer at a level that broadly aligns with this tailored P/E benchmark.

On balance, Pfizer appears to be trading at roughly fair value on its earnings multiple.

The Pfizer Narrative: What Would Justify Today's Price?

With Pfizer trading close to the earnings multiple that the earlier checks suggest, the key question becomes which future path actually supports today’s price or challenges it. Simply Wall St Narratives on Pfizer sit on the Community page and spell out the specific combinations of growth, margins and earnings that would need to play out for the stock to be worth materially more or less than it is now. Each narrative links its number to a clear view on where Pfizer’s growth, profitability and risks go next, giving you something concrete to compare against as fresh information comes through.

Community views on Pfizer sit far apart, with one camp leaning into the pipeline story and another fixated on patent and pricing pressure.

Bull case: 15% undervalued

"Robust expansion of Pfizer's late-stage pipeline, especially in oncology and rare diseases, with multiple high-potential launches and label expansions, stands to drive sustained long-term revenue and earnings growth by addressing rising global demand for therapies as the population ages..."

Bear case: roughly fairly valued

"The company's revenue trajectory is threatened by the accelerating loss of market exclusivity on major drugs such as Eliquis and Ibrance, both of which are expected to lose patent protection by 2027, resulting in a dramatic revenue cliff as generic and biosimilar competitors erode market share and profitability..."

Do you think there's more to the story for Pfizer? Head over to our Community to see what others are saying!

The Bottom Line

Pfizer appears to be trading at roughly a fair level based on its current P/E, with neither a clear discount nor an obvious premium. That puts the focus firmly on how its pipeline, especially in oncology and weight loss, offsets patent and pricing pressure over time. For you as an investor, the key question is whether Pfizer can convert that pipeline into durable earnings that justify holding a market-level multiple, or whether legal and patent risks steadily reduce what the stock is worth.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.